Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease
Thyroid eye disease (TED) is a challenging autoimmune disorder that often requires therapeutic intervention. Glucocorticoids (GCs), particularly in intravenous (IV) regimens, remain the first-line treatment due to their strong anti-inflammatory and immunosuppressive effects. This paper focuses on t...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-01-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/57699 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545137187618816 |
|---|---|
| author | Julia Ryniecka Maciej Wojszczyk Damian Zys Piotr Pasek Julia Kulbacka Michalina Wójcikiewicz Marta Chuncia-Ileczko Julia Kacperczyk Filip Arczewski Karol Dziedzic |
| author_facet | Julia Ryniecka Maciej Wojszczyk Damian Zys Piotr Pasek Julia Kulbacka Michalina Wójcikiewicz Marta Chuncia-Ileczko Julia Kacperczyk Filip Arczewski Karol Dziedzic |
| author_sort | Julia Ryniecka |
| collection | DOAJ |
| description |
Thyroid eye disease (TED) is a challenging autoimmune disorder that often requires therapeutic intervention. Glucocorticoids (GCs), particularly in intravenous (IV) regimens, remain the first-line treatment due to their strong anti-inflammatory and immunosuppressive effects. This paper focuses on the efficacy, protocols, and safety profiles of selenium supplementation and glucocorticoid therapy, emphasizing its central role in TED management. Alternative therapies, such as teprotumumab, rituximab, and tocilizumab, are briefly discussed as potential options for patients with moderate-to-severe TED, who are unresponsive or intolerant to glucocorticoids. Adherence to recommended dosing protocols and careful monitoring of adverse effects are essential to optimize treatment outcomes.
|
| format | Article |
| id | doaj-art-e925a55a57c64788819983690a8ff58d |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-e925a55a57c64788819983690a8ff58d2025-02-03T08:23:59ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-01-013710.12775/QS.2025.37.57699Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye DiseaseJulia Ryniecka0https://orcid.org/0009-0000-5937-9498Maciej Wojszczyk1https://orcid.org/0009-0002-8668-8821Damian Zys2https://orcid.org/0009-0003-6578-6710Piotr Pasek3https://orcid.org/0009-0001-6218-9887Julia Kulbacka4https://orcid.org/0009-0005-1181-9104Michalina Wójcikiewicz5https://orcid.org/0009-0003-3671-1410Marta Chuncia-Ileczko6https://orcid.org/0009-0000-0913-9752Julia Kacperczyk7https://orcid.org/0009-0007-6354-301XFilip Arczewski8https://orcid.org/0009-0008-5179-7255Karol Dziedzic9https://orcid.org/0009-0007-8317-723XMedical University of Lodz, Al T .Kosciuszki 4, 90-419 Lodz, PolandUniversity Clinical Hospital No. 1 of the Medical University of Lodz, ul. Kopcińskiego 22, 90-153 Łódź University Clinical Hospital No. 1 of the Medical University of Lodz, ul. Kopcińskiego 22, 90-153 Lodz, PolandCopernicus Memorial Hospital, ul. Pabianicka 62, 93-513 Lodz, PolandCentral Teaching Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Lodz, PolandCentral Teaching Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland Central Teaching Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Lodz, PolandMedical University of Lodz, Al. T. Kosciuszki 4, 90–419 Lodz, PolandMedical University of Lodz, Al T .Kosciuszki 4, 90-419 Lodz, PolandMedical University of Lodz, Al T .Kosciuszki 4, 90-419 Lodz, Poland Thyroid eye disease (TED) is a challenging autoimmune disorder that often requires therapeutic intervention. Glucocorticoids (GCs), particularly in intravenous (IV) regimens, remain the first-line treatment due to their strong anti-inflammatory and immunosuppressive effects. This paper focuses on the efficacy, protocols, and safety profiles of selenium supplementation and glucocorticoid therapy, emphasizing its central role in TED management. Alternative therapies, such as teprotumumab, rituximab, and tocilizumab, are briefly discussed as potential options for patients with moderate-to-severe TED, who are unresponsive or intolerant to glucocorticoids. Adherence to recommended dosing protocols and careful monitoring of adverse effects are essential to optimize treatment outcomes. https://apcz.umk.pl/QS/article/view/57699Thyroid eye disease (TED)glucocorticoids (GCs)mild TEDmoderate-to-severe TEDsight-threatening TEDintravenous glucocorticoids (IVGCs) |
| spellingShingle | Julia Ryniecka Maciej Wojszczyk Damian Zys Piotr Pasek Julia Kulbacka Michalina Wójcikiewicz Marta Chuncia-Ileczko Julia Kacperczyk Filip Arczewski Karol Dziedzic Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease Quality in Sport Thyroid eye disease (TED) glucocorticoids (GCs) mild TED moderate-to-severe TED sight-threatening TED intravenous glucocorticoids (IVGCs) |
| title | Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease |
| title_full | Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease |
| title_fullStr | Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease |
| title_full_unstemmed | Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease |
| title_short | Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease |
| title_sort | review of current first line pharmacotherapy strategies for thyroid eye disease |
| topic | Thyroid eye disease (TED) glucocorticoids (GCs) mild TED moderate-to-severe TED sight-threatening TED intravenous glucocorticoids (IVGCs) |
| url | https://apcz.umk.pl/QS/article/view/57699 |
| work_keys_str_mv | AT juliaryniecka reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT maciejwojszczyk reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT damianzys reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT piotrpasek reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT juliakulbacka reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT michalinawojcikiewicz reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT martachunciaileczko reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT juliakacperczyk reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT filiparczewski reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease AT karoldziedzic reviewofcurrentfirstlinepharmacotherapystrategiesforthyroideyedisease |